%A Simoni,Léa %A Delgado,Virginia %A Ruer-Laventie,Julie %A Bouis,Delphine %A Soley,Anne %A Heyer,Vincent %A Robert,Isabelle %A Gies,Vincent %A Martin,Thierry %A Korganow,Anne-Sophie %A San Martin,Bernardo Reina %A Soulas-Sprauel,Pauline %D 2018 %J Frontiers in Immunology %C %F %G English %K lupus,B cells,Trib1,mouse model,Ig secretion,Negative regulator %Q %R 10.3389/fimmu.2018.00373 %W %L %M %P %7 %8 2018-March-15 %9 Original Research %+ Pauline Soulas-Sprauel,CNRS UPR 3572 “Immunopathology and Therapeutic Chemistry”/Laboratory of Excellence Medalis, Institute of Molecular and Cellular Biology (IBMC),France,soulaspa@unistra.fr %+ Pauline Soulas-Sprauel,UFR Médecine, Université de Strasbourg,France,soulaspa@unistra.fr %+ Pauline Soulas-Sprauel,Department of Clinical Immunology and Internal Medicine, National Reference Center for Autoimmune Diseases, Hôpitaux Universitaires de Strasbourg,France,soulaspa@unistra.fr %+ Pauline Soulas-Sprauel,UFR Sciences pharmaceutiques, Université de Strasbourg,France,soulaspa@unistra.fr %# %! Immunosuppressive role of Trib1 %* %< %T Trib1 Is Overexpressed in Systemic Lupus Erythematosus, While It Regulates Immunoglobulin Production in Murine B Cells %U https://www.frontiersin.org/articles/10.3389/fimmu.2018.00373 %V 9 %0 JOURNAL ARTICLE %@ 1664-3224 %X Systemic lupus erythematosus (SLE) is a severe and heterogeneous autoimmune disease with a complex genetic etiology, characterized by the production of various pathogenic autoantibodies, which participate in end-organ damages. The majority of human SLE occurs in adults as a polygenic disease, and clinical flares interspersed with silent phases of various lengths characterize the usual evolution of the disease in time. Trying to understand the mechanism of the different phenotypic traits of the disease, and considering the central role of B cells in SLE, we previously performed a detailed wide analysis of gene expression variation in B cells from quiescent SLE patients. This analysis pointed out an overexpression of TRIB1. TRIB1 is a pseudokinase that has been implicated in the development of leukemia and also metabolic disorders. It is hypothesized that Trib1 plays an adapter or scaffold function in signaling pathways, notably in MAPK pathways. Therefore, we planned to understand the functional significance of TRIB1 overexpression in B cells in SLE. We produced a new knock-in model with B-cell-specific overexpression of Trib1. We showed that overexpression of Trib1 specifically in B cells does not impact B cell development nor induce any development of SLE symptoms in the mice. By contrast, Trib1 has a negative regulatory function on the production of immunoglobulins, notably IgG1, but also on the production of autoantibodies in an induced model. We observed a decrease of Erk activation in BCR-stimulated Trib1 overexpressing B cells. Finally, we searched for Trib1 partners in B cells by proteomic analysis in order to explore the regulatory function of Trib1 in B cells. Interestingly, we find an interaction between Trib1 and CD72, a negative regulator of B cells whose deficiency in mice leads to the development of autoimmunity. In conclusion, the overexpression of Trib1 could be one of the molecular pathways implicated in the negative regulation of B cells during SLE.